Form 4: Allogene Therapeutics Director Vicki Sato Granted 144,400 Stock Options

Allogene Therapeutics, Inc. Director Vicki L. Sato was granted 144,400 stock options with an exercise price of $1.29, vesting over 12 months.

Summary

• Vicki L. Sato, a Director of Allogene Therapeutics, Inc. (ALLO), was granted 144,400 stock options.
• The stock options have an exercise price of $1.29 per share.
• The options were granted on June 18, 2025, and will vest in 12 equal monthly installments from this date.
• The options become exercisable starting June 18, 2025, as they vest.
• The expiration date for these stock options is June 18, 2035.
• Following this transaction, Ms. Sato directly beneficially owns 144,400 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a routine grant of stock options to a director, which is a standard compensation practice and generally viewed as a neutral to slightly positive event as it aligns the director's interests with the company's long-term performance.

Positives

• The grant of 144,400 stock options to Director Vicki L. Sato aligns her interests with shareholder value creation, as the options gain value with an increase in the company's stock price.
• The options have a 10-year expiration period (until June 18, 2035), providing a long-term incentive for the director.

Negatives

• NA

Risks

• NA

Future Outlook

This Form 4 filing reports an insider equity grant and does not contain forward-looking statements regarding Allogene Therapeutics, Inc.'s financial performance, strategic outlook, or future business operations.

Industry Context

The grant of stock options to a director is a common and standard practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies. This mechanism is widely used to incentivize long-term commitment, align the interests of board members with those of shareholders, and serve as a component of executive and director compensation packages.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector like Allogene Therapeutics.
• The exercise price of $1.29 per share is typically set at the market price on the grant date, which is common for incentive stock options.
• A 10-year expiration period for stock options is also a common industry standard, providing a long-term incentive horizon.
• Vesting over 12 equal monthly installments is a relatively short vesting period for director options, which sometimes vest annually or over longer periods, but it is a common and acceptable practice.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grant of 144,400 stock options to Vicki L. Sato, a Director of Allogene Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's incentives with shareholder value creation, as the options gain value if the stock price increases. However, it also represents potential future dilution if and when these options are exercised.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Vesting of the 144,400 stock options in 12 equal monthly installments, commencing from June 18, 2025.
• Potential exercise of vested stock options by Vicki L. Sato at any point between their vesting date and the expiration date of June 18, 2035.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Vicki Sato, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant